Irish biotech Opsona Therapeutics recently raised $43 million with the help of four corporate VCs, for use in developing its potential first-in-class product for preventing delayed graft function in high-risk renal transplant patients.

Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research/analytical instrumentation and reagent sectors.

A roundup of recent medtech strategic alliances, mergers & acquisitions and financings.